Skip to main content

Table 4 Association between hippocampus dose and neurocognitive test deterioration

From: Hippocampus-sparing radiotherapy using volumetric modulated arc therapy (VMAT) to the primary brain tumor: the result of dosimetric study and neurocognitive function assessment

  Mean dose (EQD2/2)
  Bilateral hippocampi P value Right hippocampus P value Left hippocampus P value
SVLT-Total recall   0.033a   0.398   0.013a
 No Deterioration (n = 23) 10.6 ± 6.5   15.7 ± 16.8   11.8 ± 14.1  
 Deterioration (n = 3) 20.3 ± 11.5   7.2 ± 1.7   37.7 ± 27.6  
SVLT-Delayed recall   0.115   0.558   0.074
 No Deterioration (n = 24) 11.0 ± 6.7   15.2 ± 16.6   13.1 ± 15.0  
 Deterioration (n = 2) 19.8 ± 16.3   8.2 ± 0.1   36.0 ± 38.9  
SVLT-Recognition   0.003a   0.427   0.001a
 No Deterioration (n = 23) 10.2 ± 6.0   13.8 ± 15.8   11.1 ± 11.7  
 Deterioration (n = 3) 23.3 ± 9.4   21.8 ± 19.5   43.1 ± 30.9  
RCFT-COPY   0.469   0.211   0.261
 No Deterioration (n = 20) 11.1 ± 6.6   16.9 ± 17.7   12.7 ± 14.9  
 Deterioration (n = 6) 13.7 ± 10.7   7.5 ± 3.7   22.0 ± 24.6  
RCFT-Immediate recall   0.156   0.513   0.081
 No Deterioration (n = 24) 11.1 ± 6.6   15.3 ± 16.5   13.1 ± 15.0  
 Deterioration (n = 2) 19.0 ± 17.4   7.4 ± 1.2   36.0 ± 39.4  
RCFT-Delayed recall   0.156   0.513   0.081
 No Deterioration (n = 24) 11.1 ± 6.6   15.3 ± 16.5   13.1 ± 15.0  
 Deterioration (n = 2) 19.0 ± 17.4   7.4 ± 1.2   35.6 ± 39.4  
RCFT-Recognition   0.042a   0.406   0.257
 No Deterioration (n = 23) 10.6 ± 6.5   13.8 ± 16.0   13.4 ± 15.2  
 Deterioration (n = 3) 19.9 ± 11.5   22.1 ± 20.9   25.8 ± 32.7  
  1. Numbers are represented as mean ± SD
  2. SVLT Seoul Verbal Learning Test, RCFT Rey Complex Figure Test and Recognition Trial
  3. aindicate statistical significance by student’s t-test